l-METHYL-2-MERCAPTOIMIDAZOLE: A NEW ACTIVE ANTITHYROID AGENT*
| Autor: | Robert W. Sjogren, Elmer C. Bartels |
|---|---|
| Rok vydání: | 1951 |
| Předmět: |
Drug
endocrine system medicine.medical_specialty endocrine system diseases Endocrinology Diabetes and Metabolism medicine.medical_treatment media_common.quotation_subject Clinical Biochemistry Pharmacology Methylthiouracil Biochemistry chemistry.chemical_compound Endocrinology Internal medicine medicine media_common business.industry Antithyroid agent Biochemistry (medical) Thiouracil Clinical trial chemistry Iodothiouracil Toxicity Propylthiouracil business medicine.drug |
| Zdroj: | The Journal of Clinical Endocrinology & Metabolism. 11:1057-1062 |
| ISSN: | 1945-7197 0021-972X |
| Popis: | SINCE thiouracil, the first antithyroid drug, became available, additional related compounds have received clinical trial. Chief among the group (Table 1) are thiourea, thiobarbital, aminothiouracil, propylthiouracil, methylthiouracil, iodothiouracil, Meprocil (a combination of methylthiouracil and propylthiouracil) and the newest member, 1-methyl- 2-mercaptoimidazole (Tapazole).1 As each new antithyroid drug becomes available it not only promptly receives clinical trial to determine its antithyroid effectiveness and dosage but, more important, the incidence of toxicity, since there is a constant effort to find a drug which can be safely administered. When propylthiouracil became available and the incidence of reactions was found to be only 1.6 per cent, the use of thiouracil and thiobarbital was abandoned because of their higher reaction rates. Similarly, methylthiouracil is not routinely used because it has a reaction incidence of 13 per cent. Clinical experience is now being gained with the newest anti... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|